AHCO Quote, Financials, Valuation and Earnings

Cutera has a net margin of 3.41% compared to AdaptHealth's net margin of --. AdaptHealth's return on equity of 6% beat Cutera's return on equity of --.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 9116.59%. Given that Cutera has higher upside potential than AdaptHealth, analysts believe Cutera is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Cutera has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.755%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Cutera quarterly revenues of --. AdaptHealth's net income of $50.3M is higher than Cutera's net income of --. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 0.00x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of 3.41% compared to AdaptHealth's net margin of 12.11%. AdaptHealth's return on equity of 6% beat Electromed's return on equity of 15.91%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Electromed has higher upside potential than AdaptHealth, analysts believe Electromed is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Electromed quarterly revenues of $16.3M. AdaptHealth's net income of $50.3M is higher than Electromed's net income of $2M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of 3.41% compared to AdaptHealth's net margin of -2.16%. AdaptHealth's return on equity of 6% beat Myomo's return on equity of -48.64%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 70.52%. Given that Myomo has higher upside potential than AdaptHealth, analysts believe Myomo is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Myomo quarterly revenues of $12.1M. AdaptHealth's net income of $50.3M is higher than Myomo's net income of -$260.1K. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of 3.41% compared to AdaptHealth's net margin of -118.53%. AdaptHealth's return on equity of 6% beat Stereotaxis's return on equity of -139.2%.

AdaptHealth has a consensus price target of $13.00, signalling upside risk potential of 35.28%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Stereotaxis has higher upside potential than AdaptHealth, analysts believe Stereotaxis is more attractive than AdaptHealth.

AdaptHealth has a beta of 1.302, which suggesting that the stock is 30.157% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

AdaptHealth has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AdaptHealth pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

AdaptHealth quarterly revenues are $1.5B, which are larger than Stereotaxis quarterly revenues of $6.3M. AdaptHealth's net income of $50.3M is higher than Stereotaxis's net income of -$7.5M. Notably, AdaptHealth's price-to-earnings ratio is 16.02x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AdaptHealth is 0.40x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.